The ALCMI Consortium is a dedicated, international network of lung cancer clinical research physicians from the world's most recognized and prestigious oncology medical institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials.
We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.
ALCMI’s Master Collaboration Agreements with these organizations allow us to help investigators rapidly launch clinical trials, especially compared to standard pharmaceutical industry norms.
All ALCMI Consortium trials adhere to the International Conference of Harmonization (ICH) standards, Good Clinical Practice (GCP) best practices, and U.S. Food and Drug Administration (FDA) regulations.
“ALCMI is the place to find engaged cancer patients who understand the importance of research participation. A truly valuable network of lung cancer specialists doing innovative research into the causes of and treatments of lung cancer.”
— Dr. Jorge J. Nieva, USC Norris Comprehensive Cancer Center
